ICON Public Company (ICLR) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue fell short due to large customer budget cuts, biotech award delays, and vaccine project cancellations, with cost actions underway and full benefits expected in 2025.

• Strategic partnerships expanded, including three new top-30 pharma wins and a new top 10 pharma partnership, supporting pipeline and medium-term growth.

• Revenue growth outside the top two customers is expected in the mid-single digits year-over-year for 2024.

• Cost management and process improvements are being implemented, with benefits expected in Q4 and 2025.

Financial highlights

• Q3 2024 revenue was $2,030 million, down 1.2% year-over-year; adjusted EBITDA was $418.8 million (20.6% margin).

• Adjusted net income was $279.2 million ($3.35 per share), up 1.5% year-over-year; GAAP net income was $197.1 million ($2.36 per share), up 19.8%.

• Free cash flow for Q3 was $359.4 million, with trailing twelve months free cash flow at $1,229 million.

• Backlog reached a record $24.3 billion, up 9.4% year-over-year.

• Net debt at quarter-end was $2.7 billion, with a leverage ratio of 1.6x net debt to adjusted EBITDA.

Outlook and guidance

• Full-year 2024 revenue guidance is $8,260–$8,300 million, a 1.7%–2.2% increase year-over-year; adjusted EPS guidance is $13.90–$14.10, up 8.7%–10.2%.

• Free cash flow guidance for 2024 remains at ~$1.1 billion; capex expected at ~$150 million.

• Book-to-bill ratio targeted at 1.2–1.3x on a trailing twelve-month basis.

• Management expects Q4 headwinds to persist and is realigning resources accordingly.